A cancer diagnosis usually means bracing for one of three things: a scalpel, chemotherapy drugs, or radiation. Doctors and patients now have a genuinely different option for one specific cancer type — a technology that destroys tumors using nothing but focused sound waves.
Key Takeaways
- The treatment, called histotripsy, uses focused ultrasound waves to mechanically break apart tumor tissue from outside the body, without cutting, chemotherapy drugs, or radiation.
- The FDA approved it specifically for liver tumors — both primary liver cancer and cancer that has spread to the liver from elsewhere in the body. It has not been approved for cancer generally.
- The technology was developed at the University of Michigan and is now sold commercially by HistoSonics under the name Edison.
- Because the treatment can be precisely targeted, it avoids much of the collateral tissue damage associated with radiation, and comes with a far shorter recovery time than surgery.
How It Actually Works
Histotripsy relies on focusing high-energy ultrasound waves to a single, precise point inside the body, concentrating enough energy there to form microscopic bubbles that mechanically break apart the targeted tissue — a process that happens without any incision, without radiation exposure, and without chemotherapy drugs entering the bloodstream. The Edison platform delivering the treatment includes built-in diagnostic ultrasound imaging, the same type of imaging used for pregnancy scans, allowing physicians to see the tumor and monitor the treatment in real time as it happens rather than relying only on pre-treatment scans.
The precision is a meaningful advantage over other non-surgical options. Radiation therapy affects healthy tissue along its entire path through the body, not just the tumor itself. Histotripsy, by contrast, concentrates its effect specifically at the targeted point, largely sparing the surrounding healthy liver tissue.
What the Approval Actually Covers
It’s worth being precise about scope here: the FDA’s approval is specifically for liver tissue, covering both primary liver tumors and tumors that have metastasized to the liver from cancers elsewhere in the body. It is not a general cancer treatment, and it hasn’t been approved for other tumor types like breast, lung, or prostate cancer. The approval followed a clinical trial that began in 2021 at the University of Michigan’s Rogel Cancer Center and other sites, treating patients with liver tumors and meeting the trial’s pre-specified effectiveness and safety targets.
“Histotripsy is an exciting new technology that, although it is in early stages of clinical use, may provide a noninvasive treatment option for patients with liver cancer,” said Dr. Mishal Mendiratta-Lala, a professor of radiology at Michigan Medicine and the trial’s principal investigator, adding that it may eventually be combined with systemic therapies like chemotherapy for a stronger combined effect rather than necessarily replacing them entirely.
An Unexpected Extra Benefit Being Studied
Beyond directly destroying targeted tissue, researchers are investigating a secondary effect: as the body clears away the mechanically broken-down tumor debris, some preclinical research in animals suggests the immune system may “learn” to recognize similar cancer cells as threats elsewhere in the body, a phenomenon sometimes called an abscopal-like effect. This research is still in earlier, preclinical stages and hasn’t yet been confirmed to work the same way in human patients, but it’s a promising area future studies are expected to explore further.
What This Means If You or a Loved One Has Liver Cancer
For patients with primary or metastatic liver tumors, histotripsy adds a genuinely new option to the standard toolkit of surgery, radiation, chemotherapy, and thermal ablation — one that avoids the physical toll and recovery time associated with more invasive approaches. It’s still a relatively new technology in clinical use, so availability may currently be limited to hospitals equipped with the Edison platform. Anyone facing a liver cancer diagnosis should ask their oncologist directly whether they’d be a candidate for histotripsy as part of their treatment planning.
Source: University of Michigan, “Tumor-destroying sound waves receive FDA approval for liver treatment in humans” (Michigan Medicine, Michigan News).